Profile data is unavailable for this security.
About the company
PT Kalbe Farma Tbk is an Indonesia-based company, which is engaged in the development, manufacturing and trading of pharmaceutical products including human medicines and consumer health products. Its business divisions include Prescription Pharmaceutical, Consumer Health Division, Nutritionals, and Distribution and Logistic divisions. The Prescription Pharmaceuticals division provides a range of products for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over the counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising of powdered milk products for all age segments. It also offers a selection of non-milk nutritional products. The Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.
- Revenue in IDR (TTM)30.45tn
- Net income in IDR2.77tn
- Incorporated1967
- Employees13.11k
- LocationKalbe Farma Tbk PTGedung KALBE Let.Jend Suprato Kav. 4JAKARTA PUSAT 10510IndonesiaIDN
- Phone+62 2 142873888
- Fax+62 214256326
- Websitehttp://www.kalbe.co.id
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xiamen Amoytop Biotech Co Ltd | 4.69tn | 1.24tn | 60.31tn | 1.96k | 48.59 | 14.38 | -- | 12.85 | 1.37 | 1.37 | 5.16 | 4.61 | 1.02 | 0.9553 | 6.41 | 1,071,593.00 | 26.92 | 17.96 | 32.16 | 21.02 | 92.80 | 90.48 | 26.45 | 19.17 | 2.86 | -- | 0.0042 | 26.95 | 37.55 | 36.19 | 93.52 | 103.28 | 81.61 | -- |
| Biocon Ltd | 28.29tn | 2.32tn | 61.91tn | 3.41k | 26.64 | -- | 10.60 | 2.19 | 10.03 | 10.03 | 122.21 | -- | -- | -- | -- | 42,877,050.00 | -- | 4.31 | -- | 5.91 | 67.17 | 61.34 | 10.19 | 10.87 | -- | 1.66 | -- | 8.49 | 36.54 | 22.03 | -28.64 | 4.44 | 13.50 | 24.57 |
| GlaxoSmithKline Pharmaceuticals Limited | 6.41tn | 1.02tn | 61.93tn | 3.68k | 60.46 | -- | 53.52 | 9.66 | 31.23 | 31.23 | 195.53 | -- | -- | -- | -- | 8,998,269.00 | -- | 9.94 | -- | 16.01 | 60.37 | 54.71 | 15.97 | 11.58 | -- | 447.28 | -- | 196.13 | -0.8025 | 2.35 | 59.58 | 11.62 | -35.79 | 12.83 |
| Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 3.44tn | -1.28tn | 62.75tn | 1.42k | -- | 12.06 | -- | 18.23 | -4.04 | -4.04 | 9.08 | 11.50 | -- | -- | -- | 1,177,697.00 | -- | -- | -- | -- | 49.28 | -- | -37.27 | -- | 2.47 | -6.17 | 0.0251 | -- | 91.62 | -- | 6.81 | -- | -- | -- |
| Kalbe Farma Tbk PT | 30.45tn | 2.77tn | 66.33tn | 13.11k | 23.65 | 3.06 | 18.88 | 2.18 | 59.83 | 59.83 | 658.28 | 463.05 | 1.12 | 2.74 | 6.57 | 2,322,943,000.00 | 10.23 | 12.50 | 12.86 | 15.48 | 37.87 | 41.21 | 9.12 | 11.26 | 2.81 | 152.98 | 0.0262 | -- | 5.24 | 7.64 | -18.20 | 2.40 | -3.00 | -- |
| IPCA Laboratories Ltd | 13.91tn | 1.09tn | 66.43tn | 16.17k | 60.79 | -- | 36.65 | 4.77 | 22.25 | 22.25 | 283.32 | -- | -- | -- | -- | 4,444,876.00 | -- | 11.95 | -- | 15.34 | 65.47 | 59.17 | 8.45 | 13.77 | -- | 12.99 | -- | 12.02 | 7.11 | 13.72 | -46.69 | 14.51 | 29.32 | 51.57 |
| Tianjin Pharmcetl Da Ren Tang Grp Cp Ltd | 18.37tn | 2.20tn | 67.08tn | 4.62k | 25.79 | 3.86 | -- | 3.65 | 1.28 | 1.28 | 10.70 | 8.58 | 0.8066 | 3.13 | 3.81 | 1,780,107.00 | 9.50 | 8.96 | 14.09 | 12.80 | 43.04 | 40.82 | 11.78 | 10.67 | 1.54 | -- | 0.1256 | 56.93 | -0.3266 | 5.28 | 14.49 | 11.93 | -4.33 | 42.22 |
| Holder | Shares | % Held |
|---|---|---|
| RBC Global Asset Management (UK) Ltd.as of 29 Feb 2024 | 940.48m | 2.01% |
| First Sentier Investors (Hong Kong) Ltd.as of 31 Dec 2023 | 864.38m | 1.84% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 727.37m | 1.55% |
| First Sentier Investors (UK) IM Ltd.as of 31 Mar 2024 | 691.52m | 1.48% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 644.42m | 1.38% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 555.66m | 1.19% |
| Invesco Advisers, Inc.as of 29 Feb 2024 | 446.53m | 0.95% |
| PT Schroder Investment Management Indonesiaas of 31 Dec 2022 | 333.49m | 0.71% |
| BlackRock Advisors (UK) Ltd.as of 04 Apr 2024 | 265.00m | 0.57% |
| MFS International Singapore Pte. Ltd.as of 29 Feb 2024 | 224.71m | 0.48% |
